Dinoprostone
Cervidil, Prepidil (dinoprostone) is a small molecule pharmaceutical. Dinoprostone was first approved as Prostin e2 on 1982-01-01. It is used to treat fetal death, gestational trophoblastic disease, and uterine neoplasms in the USA. It is known to target solute carrier organic anion transporter family member 2A1, prostaglandin E2 receptor EP2 subtype, prostaglandin E2 receptor EP3 subtype, prostaglandin E2 receptor EP4 subtype, prostaglandin E2 receptor EP1 subtype, and solute carrier organic anion transporter family member 3A1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Cervidil, Prepidil (discontinued: Prostin e2)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| fetal death | HP_0003826 | D005313 | — |
| gestational trophoblastic disease | — | D031901 | O01.9 |
| uterine neoplasms | EFO_0003859 | D014594 | C55 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
335 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 7 | 6 | 8 | 13 | 8 | 42 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 4 | 16 | 5 | 2 | 27 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 2 | 7 | 9 | 2 | 4 | 23 |
| Postoperative pain | D010149 | G89.18 | — | 2 | 8 | 4 | 5 | 19 | |
| Healthy volunteers/patients | — | 10 | — | — | 1 | 3 | 14 | ||
| Actinic keratosis | D055623 | L57.0 | 1 | — | 5 | 5 | 1 | 12 | |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | 2 | 5 | 2 | 10 |
| Pulpitis | D011671 | EFO_1001139 | K04.0 | — | 4 | 3 | 3 | 2 | 9 |
| Ankle injuries | D016512 | S93.4 | — | 2 | 4 | 1 | 2 | 8 | |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | — | 2 | 4 | — | 6 |
Show 50 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute pain | D059787 | R52 | — | 1 | 6 | — | — | 6 | |
| Inflammation | D007249 | 3 | — | 1 | — | 1 | 5 | ||
| Soft tissue injuries | D017695 | — | 1 | 2 | — | 1 | 4 | ||
| Dental pins | D003772 | — | 1 | 2 | — | — | 3 | ||
| Sciatica | D012585 | HP_0011868 | M54.3 | — | — | 1 | — | 1 | 2 |
| Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | 1 | 1 | — | 1 | 2 |
| Procedural pain | D000073818 | — | — | 2 | — | — | 2 | ||
| Myalgia | D063806 | HP_0003326 | M79.1 | — | — | 1 | — | — | 1 |
| Sunburn | D013471 | EFO_0003958 | L55 | — | — | 1 | — | — | 1 |
| Colic | D003085 | HP_0011848 | R10.83 | — | — | 1 | — | — | 1 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gout | D006073 | EFO_0004274 | M10 | — | 1 | — | — | 1 | 2 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 2 | — | — | — | 2 |
| Gouty arthritis | D015210 | — | 1 | — | — | — | 1 | ||
| Basal cell neoplasms | D018295 | — | 1 | — | — | — | 1 | ||
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | 1 | 1 | — | — | — | 1 |
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | 1 | |
| Musculoskeletal pain | D059352 | — | 1 | — | — | — | 1 | ||
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | — | 1 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | 1 | 3 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | — | — | — | 1 | 2 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | 1 | — | — | — | 1 | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | — | 1 |
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 | ||
| Chronic renal insufficiency | D051436 | N18 | 1 | — | — | — | — | 1 | |
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Biological availability | D001682 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | — | — | 2 | 2 |
| Pathologic dilatation | D004108 | — | — | — | — | 2 | 2 | ||
| Keratoconus | D007640 | EFO_0004223 | H18.6 | — | — | — | — | 2 | 2 |
| Regeneration | D012038 | — | — | — | — | 2 | 2 | ||
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 2 | 2 | |
| Hemostasis | D006487 | — | — | — | — | 1 | 1 | ||
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | — | — | — | 1 | 1 |
| Synovitis | D013585 | EFO_0008997 | M67.5 | — | — | — | — | 1 | 1 |
Show 24 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DINOPROSTONE |
| INN | dinoprostone |
| Description | Prostaglandin E2 is prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. It has a role as an oxytocic, a human metabolite and a mouse metabolite. It is a conjugate acid of a prostaglandin E2(1-). |
| Classification | Small molecule |
| Drug class | prostaglandins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O |
Target
Agency Approved
No data
Alternate
SLCO2A1
SLCO2A1
PTGER2
PTGER2
PTGER3
PTGER3
PTGER4
PTGER4
PTGER1
PTGER1
SLCO3A1
SLCO3A1
Organism
Homo sapiens
Gene name
SLCO2A1
Gene synonyms
OATP2A1, SLC21A2
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 2A1
Protein synonyms
matrin F/G 1, OATP2A1, PGT, PHOAR2, Prostaglandin transporter, SLC21A2, solute carrier family 21 (prostaglandin transporter), member 2, Solute carrier family 21 member 2
Uniprot ID
Mouse ortholog
Slco2a1 (24059)
solute carrier organic anion transporter family member 2A1 (Q9EPT5)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,420 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
72,409 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more